Nuvilex (NASDAQ:PMCB) Shares Down 2.5% – Time to Sell?

Nuvilex Inc. (NASDAQ:PMCB) dropped 2.5% on Monday. The stock traded as low as $0.3851 and last traded at $0.3901. 73,620 shares traded hands during mid-day trading, a decline of 82% from the average session volume of 405,929 shares. The stock had previously closed at $0.4001.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut shares of Nuvilex from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 2nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.

Nuvilex Price Performance

The firm has a market capitalization of $4.44 million, a price-to-earnings ratio of -0.18 and a beta of 0.68. The stock has a fifty day moving average of $0.49 and a two-hundred day moving average of $0.65.

Nuvilex (NASDAQ:PMCB) last announced its earnings results on Monday, September 14th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.48).

Nuvilex Company Profile

Nuvilex, Inc was a biotechnology company that later changed its name to PharmaCyte Biotech, Inc and continued trading under the Nasdaq symbol PMCB. The company focused on developing treatments for advanced cancer, with its principal program aimed at pancreatic cancer.

The company’s lead investigational approach, known as Cell-in-a-Box, used encapsulated, genetically engineered cells designed to convert ifosfamide into cancer-fighting metabolites at or near a tumor. The strategy was intended to deliver chemotherapy locally while potentially reducing exposure to healthy tissue.